Mark J. Levin Net Worth

The estimated Net Worth of Mark J Levin is at least $54.1 Million dollars as of 22 July 2019. Mr Levin owns over 81,250 units of Fulcrum Therapeutics Inc stock worth over $52,765,488 and over the last 9 years he sold FULC stock worth over $1,226,400. In addition, he makes $73,000 as Exec. Chairman at Fulcrum Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Levin FULC stock SEC Form 4 insiders trading

Mr has made over 2 trades of the Fulcrum Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 81,250 units of FULC stock worth $1,300,000 on 22 July 2019.

The largest trade he's ever made was buying 81,250 units of Fulcrum Therapeutics Inc stock on 22 July 2019 worth over $1,300,000. On average, Mr trades about 6,544 units every 50 days since 2015. As of 22 July 2019 he still owns at least 5,962,202 units of Fulcrum Therapeutics Inc stock.

You can see the complete history of Mr Levin stock trades at the bottom of the page.

Mr. Mark J. Levin biography

Mark J. Levin is the Exec. Chairman at Fulcrum Therapeutics Inc.

What is the salary of Mr Levin?

As the Exec. Chairman of Fulcrum Therapeutics Inc, the total compensation of Mr Levin at Fulcrum Therapeutics Inc is $73,000. There are 11 executives at Fulcrum Therapeutics Inc getting paid more, with Robert Gould having the highest compensation of $3,889,350.

How old is Mr Levin?

Mr Levin is 71, he's been the Exec. Chairman of Fulcrum Therapeutics Inc since . There are no older and 14 younger executives at Fulcrum Therapeutics Inc.

What's Mr Levin's mailing address?

Mark's mailing address filed with the SEC is C/O THIRD ROCK VENTURES, LLC,, 29 NEWBURY STREET, 3RD FLOOR, BOSTON, MA, 02116.

Insiders trading at Fulcrum Therapeutics Inc

Over the last 5 years, insiders at Fulcrum Therapeutics Inc have traded over $1,450,584 worth of Fulcrum Therapeutics Inc stock and bought 5,263,802 units worth $50,137,344 . The most active insiders traders include Sanofi, Plc Gsk, and Capital Management, L.P.Ra .... On average, Fulcrum Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of $868,035. The most recent stock trade was executed by Alex Sapir on 3 July 2024, trading 150,000 units of FULC stock currently worth $490,500.

What does Fulcrum Therapeutics Inc do?

what if we could regulate genes, not just discover them? what if we could treat disease at their genetic source? what if we could integrate multiple disciplines to develop breakthrough medicines? what if you could be a part of a passionate team committed to the patients we serve? we can. we will. we are. join us. we are here to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. a fulcrum is defined as the point on which a lever rests, balances and pivots. fulcrum therapeutics is intervening in gene regulatory mechanisms to unlock the information contained in the human genome. the fulcrum product engine is dedicated to bringing balance to the genetic on and off switches in disease. our approach the sequencing of the human genome has provided incredible insight into disease biology, yet the richness of biology comes from the dynamic on and off switches that control the genome – gene regulation. the fulcrum product eng

Complete history of Mr Levin stock trades at Blueprint Medicines Corp, Voyager Therapeutics Inc, and Fulcrum Therapeutics Inc

Fulcrum Therapeutics Inc executives and stock owners

Fulcrum Therapeutics Inc executives and other stock owners filed with the SEC include:

• Robert Gould,
  President, Chief Executive Officer, Director
• Owen Wallace,
  Chief Scientific Officer
• Bryan Stuart,
  Chief Operating Officer
• Dr. Judith A. Dunn Ph.D.,
  Pres of R&D and Interim Chief Medical Officer
• Bryan E. Stuart,
  Pres, CEO & Director
• Diego Cadavid,
  Senior Vice President - Clinical Development
• james Geraghty,
  Independent Director
• Kate Haviland,
  Independent Director
• Alan Ezekowitz,
  Independent Director
• James Collins,
  Independent Director
• Curtis G. Oltmans J.D.,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Mark J. Levin,
  Exec. Chairman
• Mark Levin,
  Independent Chairman of the Board
• Christina Tartaglia,
  IR Contact Officer
• Katina Dorton,
  Independent Director
• Christi Waarich,
  Director of Corp. Communications & Investor Relations
• Gregory Tourangeau,
  Controller & Principal Accounting Officer
• Esther P. Rajavelu,
  CFO & Treasurer
• Nicole T. Gallagher,
  Director of Admin.
• Peter G. Thomson,
  VP of Fin. & Accounting
• Dr. Danny Reinberg,
  Founder
• Prof. Jeannie T. Lee M.D., Ph.D.,
  Founder
• Dr. Rudolf Jaenisch M.D., Ph.D.,
  Founder
• Dr. Michael R. Green,
  Founder
• Dr. Bradley E. Bernstein M.D., Ph.D.,
  Founder
• Sonja Banks,
  
• Colin Hill,
  
• Sanofi,
  10% owner
• Rock Ventures Iii, L.P.Thir...,
  
• Dimensions Capital, L.P. 6,
  10% owner
• 32 Fund 2, Lp Section 32 Gp...,
  
• Capital, Llc Casdin Partner...,
  
• Rock Ventures Iv, L.P.Third...,
  
• Plc Gsk,
  
• Curtis Gale Oltmans,
  Chief Legal Officer
• Peter G. Thomson,
  VP Finance & Accounting
• Christopher Morabito,
  Chief Medical Officer
• Christopher Moxham,
  Chief Scientific Officer
• Judith Dunn,
  See Remarks
• Greg Tourangeau,
  Principal Accounting Officer
• Esther Rajavelu,
  Chief Financial Officer
• Rock Ventures Iii, L.P.Thir...,
  
• Alex Sapir,
  See Remarks
• Patrick Taylor Horn,
  Chief Medical Officer
• Melvin H. Iii Hayes,
  Chief Operating Officer
• Santiago Arroyo,
  Chief Medical Officer
• Capital Management, L.P.Ra ...,
  
• Alan A Musso,
  Chief Financial Officer